SCHEMBL247433

SCHEMBL247433

COc1cccc(NC(=O)C=Cc2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 9/20 1.00
MMP2 P08253 9/20 1.00
MMP9 P14780 9/20 1.00
MAPT P10636 5/20 0.79
KMT2A Q03164 4/20 0.79
ALDH1A1 P00352 4/20 0.79
TRPV1 Q8NER1 3/20 0.79
MEN1 O00255 3/20 0.79
TP53 P04637 2/20 0.79
HDAC6 Q9UBN7 1/20 0.79
CYP3A4 P08684 1/20 0.79
CYP2C9 P11712 1/20 0.79
TSHR P16473 1/20 0.79
MAPK1 P28482 1/20 0.79
CYP2C19 P33261 1/20 0.79
EGFR P00533 4/20 0.72
NPC1 O15118 4/20 0.72
RAB9A P51151 4/20 0.72
TDP1 Q9NUW8 1/20 0.72
MAOA P21397 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL247432 1.00 MMP1 (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL247434 1.00 MMP1 (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL30080242 1.00 MMP1 (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL1595342 0.88 KMT2A (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL29388461 0.88 KMT2A (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL296015 0.88 KMT2A (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL13675628 0.86 TRPV1 (1.00) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL8061581 0.86 MMP1 (0.75) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL8061578 0.86 MMP1 (0.75) MMP1MMP2MMP9MAPTKMT2A
SCHEMBL6275866 0.85 MMP1 (0.73) MMP1MMP2MMP9MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114940894-B Star-shaped temperature-resistant fracturing fluid thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2022-09-30 CN claimed
CN-114940894-A Star-shaped temperature-resistant fracturing fluid thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2022-08-26 CN claimed
CN-119462500-A Preparation method of 7- (4-chlorobutoxy) -1H-quinolin-2-one 湖南省湘中制药有限公司 2025-02-18 CN disclosed
CN-118126238-A Temperature-resistant salt-resistant shearing-resistant polyacrylamide and preparation method thereof 山东诺尔生物科技有限公司 2024-06-04 CN disclosed
CN-109776408-B Preparation method of 7-hydroxy-2-quinolinone 上海医药工业研究院 2022-12-20 CN disclosed
CN-114940894-B Star-shaped temperature-resistant fracturing fluid thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2022-09-30 CN disclosed
CN-114940894-A Star-shaped temperature-resistant fracturing fluid thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2022-08-26 CN disclosed
EP-3397636-B1 PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES HONOUR R&D (IN) 2021-08-04 EP disclosed
CN-109970705-B Method for preparing brexpiprazole intermediate and brexpiprazole by using cheap metal copper 浙江工业大学 2021-02-09 CN disclosed
US-10464931-B2 Process for the preparation of Quinolin-2(1H)-one derivatives HONOUR (R&D) (IN) 2019-11-05 US disclosed
CN-106645494-B According to a detection method of the piperazine azoles starting material in relation to substance 成都百裕制药股份有限公司 2019-09-06 CN disclosed
CN-106645494-A Detection method of brexpiprazole starting material related substances 成都百裕制药股份有限公司 2017-05-10 CN disclosed
US-20150291626-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2015-10-15 US disclosed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
EP-2925762-A1 TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM Sunovion Pharmaceuticals Inc. (US) 2015-10-07 EP disclosed
WO-2014085284-A1 TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUNOVION PHARMACEUTICALS INC. (US) 2014-06-05 WO disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
WO-2012003418-A2 FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-01-05 WO disclosed
US-20020022633-A1 Inhibitors of prenyl-protein transferase WILLIAMS THERESA M (US) 2002-02-21 US disclosed
WO-2002002108-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291626-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN MMP1 4667/4885MMP2 2920/4885MMP9 3783/4885
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors DRD2, AVPR2, NTSR2 MMP1 4851/4885MMP2 4587/4885MMP9 4776/4885
US-10464931-B2 Process for the preparation of Quinolin-2(1H)-one derivatives UGT1A1, CYP1A2, CYP1A1 MMP1 4713/4885MMP2 4218/4885MMP9 4259/4885
US-20020022633-A1 Inhibitors of prenyl-protein transferase FNTA, KRAS, FNTB MMP1 4213/4885MMP2 3386/4885MMP9 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.